CoChat

Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort

Open access

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Objective: Population-based data are lacking regarding the risk of overall and cause-specific mortality across the complete histological spectrum of non-alcoholic fatty liver disease (NAFLD). Design: This nationwide, matched cohort study included all individuals in Sweden with biopsy-confirmed NAFLD (1966 to 2017; n=10 568). NAFLD was confirmed histologically from all liver biopsies submitted to Sweden’s 28 pathology departments, after excluding other etiologies of liver disease, and further categorised as, simple steatosis, non-fibrotic steatohepatitis (NASH), non-cirrhotic fibrosis and cirrhosis. NAFLD cases were matched to ≤5 general population comparators by age, sex, calendar year and county (n=49 925). Using Cox regression, we estimated multivariable-adjusted HRs (aHRs) and 95% CIs. Results: Over a median of 14.2 years, 4,338 NAFLD patients died. Compared with controls, NAFLD patients had significantly increased overall mortality (16.9 vs 28.6/1000 PY; difference=11.7/1000 PY; aHR=1.93, 95% CI=1.86 to 2.00). Compared with controls, significant excess mortality risk was observed with simple steatosis (8.3/1000 PY, aHR=1.71, 95% CI=1.64 to 1.79), non-fibrotic NASH (13.4/1000 PY, aHR=2.14, 95% CI=1.93 to 2.38), non-cirrhotic fibrosis (18.4/1000 PY, aHR=2.44, 95% CI=2.22 to 2.69) and cirrhosis (53.6/1000 PY, aHR=3.79, 95% CI=3.34 to 4.30)(p trend <0.01). This dose-dependent gradient was similar when simple steatosis was the reference (p trend <0.01). The excess mortality associated with NAFLD was primarily from extrahepatic cancer (4.5/1000 PY, aHR=2.16, 95% CI=2.03 to 2.30), followed by cirrhosis (2.7/1000 PY, aHR=18.15, 95% CI=14.78 to 22.30), cardiovascular disease (1.4/1000 PY, aHR=1.35, 95% CI=1.26 to 1.44) and hepatocellular carcinoma (HCC) (1.2/1000 PY, aHR=11.12, 95% CI=8.65 to 14.30). Conclusion: All NAFLD histological stages were associated with significantly increased overall mortality, and this risk increased progressively with worsening NAFLD histology. Most of this excess mortality was from extrahepatic cancer and cirrhosis, while in contrast, the contributions of cardiovascular disease and HCC were modest.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2020-322786

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Cumulative Incidence of All-Cause Mortality According to the Presence and Histologic Severity* of NAFLD Abbreviations: NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; ref., reference group *NAFLD histologic severity was defined in 4 categories, as simple steatosis, NASH without fibrosis, non-cirrhotic fibrosis and cirrhosis (for details, see the eMethods section)
Figure 1. Cumulative Incidence of All-Cause Mortality According to the Presence and Histologic Severity* of NAFLD Abbreviations: NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; ref., reference group *NAFLD histologic severity was defined in 4 categories, as simple steatosis, NASH without fibrosis, non-cirrhotic fibrosis and cirrhosis (for details, see the eMethods section)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 723

Metadata

Authors
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H., & Ludvigsson, J. F.
Affiliations
  • Harvard University (US)
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Stockholm County, Sweden
  • Karolinska University Hospital (SE)
  • University of Nottingham (GB)
Corresponding author
Ludvigsson, Jonas F
Venue
Gut
Publisher
BMJ
Published
2020-10-09
Volume
70
Issue
7
Pages
1375-1382
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3092264591
Cited by
673
References
43
Citations by year
2026: 85 · 2025: 139 · 2024: 134 · 2023: 133 · 2022: 117 · 2021: 59 · 2020: 4
FWCI
56.26
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by)
Funders
  • Karolinska Institutet (Institutional Award)
  • Harvard University Center for AIDS Research (Career Development Award)
  • Crohns and Colitis Foundation (Senior Research Award)
  • Region Stockholm (Postdoctoral appointment)
  • National Institutes of Health (K23 DK122104)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
non-alcoholic fatty liver disease, mortality, liver cirrhosis, simple steatosis, cause-specific mortality, extrahepatic cancer, liver cancer, liver transplantation, liver biopsy histology, dose-response relationship, histological staging, matched cohort, excess mortality
MeSH terms
Adult, Aged, Biopsy, Cardiovascular Diseases, Female, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Registries, Retrospective Studies, Risk Factors, Sweden, Proportional Hazards Models, Case-Control Studies, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. https://app.cochat.ai/papers/10.1136/gutjnl-2020-322786
The paper
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021). Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. https://doi.org/10.1136/gutjnl-2020-322786

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.